Literature DB >> 15855321

The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.

Ruth Andrew1, Jukka Westerbacka, John Wahren, Hannele Yki-Järvinen, Brian R Walker.   

Abstract

Cortisol is regenerated from cortisone by 11beta-hydroxysteroid dehydrogenase type 1 (11HSD1), amplifying glucocorticoid action in adipose tissue and liver. 11HSD1 inhibitors are being developed for type 2 diabetes and may be most effective in obesity, where adipose 11HSD1 is increased. However, the magnitude of regeneration of cortisol in different tissues in humans is unknown, hindering understanding of the pathophysiological and therapeutic importance of 11HSD1. In eight healthy men, we infused 9,11,12,12-(2)H4-cortisol and measured tracer enrichment in the hepatic vein as an indicator of total splanchnic cortisol generation. Oral cortisone (25 mg) was then given to measure first-pass hepatic cortisol generation. In steady state, splanchnic cortisol production was 45 +/- 11 nmol/min when arterialized plasma cortisone concentration was 92 +/- 7 nmol/l. Extrapolation from hepatic cortisol generation after oral cortisone suggested that, at steady state, the liver contributes 15.2 nmol/min and extrahepatic splanchnic tissue contributes 29.8 nmol/min to the total splanchnic cortisol production. We conclude that tissues draining into the portal vein, including visceral adipose tissue, contribute substantially to the regeneration of cortisol. Thus, in addition to free fatty acids and adipokines, the portal vein delivers cortisol to the liver, and inhibition of 11HSD1 in visceral adipose tissue may indeed be valuable in ameliorating insulin resistance in obesity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855321     DOI: 10.2337/diabetes.54.5.1364

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  30 in total

Review 1.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  Estimation of maximal cortisol secretion rate in healthy humans.

Authors:  Richard I Dorin; Zhi Qiao; Clifford R Qualls; Frank K Urban
Journal:  J Clin Endocrinol Metab       Date:  2012-02-15       Impact factor: 5.958

3.  Glucocorticoids turn over slowly in human adipose tissue in vivo.

Authors:  Katherine A Hughes; Rebecca M Reynolds; Ruth Andrew; Hilary O D Critchley; Brian R Walker
Journal:  J Clin Endocrinol Metab       Date:  2010-07-14       Impact factor: 5.958

4.  Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique.

Authors:  Simmi Dube; Barbara Norby; Vishwanath Pattan; Ravi K Lingineni; Ravinder J Singh; Rickey E Carter; Ananda Basu; Rita Basu
Journal:  Diabetologia       Date:  2014-04-26       Impact factor: 10.122

5.  Liver is the site of splanchnic cortisol production in obese nondiabetic humans.

Authors:  Rita Basu; Ananda Basu; Meagan Grudzien; Paul Jung; Peer Jacobson; Michael Johnson; Ravinder Singh; Michael Sarr; Robert A Rizza
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

6.  Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.

Authors:  Roland H Stimson; Jonas Andersson; Ruth Andrew; Doris N Redhead; Fredrik Karpe; Peter C Hayes; Tommy Olsson; Brian R Walker
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

Review 7.  Obesity, sleep apnea, aldosterone, and hypertension.

Authors:  Theodore L Goodfriend
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

8.  Glucocorticoid Excess Increases Hepatic 11β-HSD-1 Activity in Humans: Implications in Steroid-Induced Diabetes.

Authors:  Simmi Dube; Michael Q Slama; Ananda Basu; Robert A Rizza; Rita Basu
Journal:  J Clin Endocrinol Metab       Date:  2015-08-26       Impact factor: 5.958

9.  Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?

Authors:  Paul M Stewart; Jeremy W Tomlinson
Journal:  Diabetes       Date:  2009-01       Impact factor: 9.461

10.  Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism.

Authors:  Helga A Sigurjonsdottir; Ruth Andrew; Roland H Stimson; Gudmundur Johannsson; Brian R Walker
Journal:  Eur J Endocrinol       Date:  2009-06-23       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.